Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0282612 (
PIN
)
2,291
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2
(
MAGI-2
) is a scaffolding protein that links cell adhesion molecules, receptors, and signaling molecules to the cytoskeleton and maintains the architecture of cell junctions.
MAGI-2
gene rearrangements have recently been described in prostate cancer. We studied the immunohistochemical expression of
MAGI-2
protein in prostate tissue. Seventy-eight radical prostatectomies were used to construct 3 tissue microarrays consisting of 512 cores, including benign tissue, benign prostatic hyperplasia, high-grade
prostatic intraepithelial neoplasia
(HGPIN), and adenocarcinoma, Gleason patterns 3 to 5. Immunohistochemistry for phosphatase and tensin homologue (PTEN) and double-stain
MAGI-2
/p63 was performed and analyzed by visual and image analysis, the latter as percent of analyzed area (%AREA), and mean optical density multiplied by %AREA (STAIN). By visual and image analysis,
MAGI-2
was significantly higher in adenocarcinoma and HGPIN compared with benign (benign versus HGPIN P < .001; benign versus adenocarcinoma, P < .001). HGPIN and adenocarcinoma did not significantly differ by either modality. Using visual intensity to distinguish benign tissue and adenocarcinoma, a receiver operating curve yielded an area under the curve of 0.902. A STAIN threshold of 1470 yielded a sensitivity of 0.66 and specificity of 0.96. There was a significant correlation between PTEN and
MAGI-2
staining for normal and benign prostatic hyperplasia, but this was lost in HGPIN and cancer. We conclude that
MAGI-2
immunoreactivity is elevated in prostate cancer and HGPIN compared with normal tissue, and suggest that
MAGI-2
may contribute to prostate carcinogenesis. This is the first report of
MAGI-2
staining by immunohistochemistry in prostate cancer.
...
PMID:MAGI-2 in prostate cancer: an immunohistochemical study. 2698 16